HK1212678A1 - 雙氰胺前體藥物 - Google Patents

雙氰胺前體藥物

Info

Publication number
HK1212678A1
HK1212678A1 HK16100480.9A HK16100480A HK1212678A1 HK 1212678 A1 HK1212678 A1 HK 1212678A1 HK 16100480 A HK16100480 A HK 16100480A HK 1212678 A1 HK1212678 A1 HK 1212678A1
Authority
HK
Hong Kong
Prior art keywords
cyanoguanidine
prodrugs
cyanoguanidine prodrugs
Prior art date
Application number
HK16100480.9A
Other languages
English (en)
Inventor
Ernst Torndal Binderup
Pernill-Julia Vig Hjarnaa
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of HK1212678A1 publication Critical patent/HK1212678A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16100480.9A 2000-11-21 2016-01-15 雙氰胺前體藥物 HK1212678A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21

Publications (1)

Publication Number Publication Date
HK1212678A1 true HK1212678A1 (zh) 2016-06-17

Family

ID=22954502

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05105842A HK1073297A1 (en) 2000-11-21 2005-07-11 Cyanoguanidine prodrugs
HK16100480.9A HK1212678A1 (zh) 2000-11-21 2016-01-15 雙氰胺前體藥物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK05105842A HK1073297A1 (en) 2000-11-21 2005-07-11 Cyanoguanidine prodrugs

Country Status (17)

Country Link
US (1) US6525077B2 (zh)
EP (2) EP1339686B1 (zh)
JP (1) JP4521157B2 (zh)
KR (1) KR100871577B1 (zh)
CN (1) CN100368401C (zh)
AU (3) AU1494702A (zh)
BR (1) BR0115514A (zh)
CA (1) CA2426601C (zh)
CZ (1) CZ305764B6 (zh)
ES (2) ES2643083T3 (zh)
HK (2) HK1073297A1 (zh)
HU (1) HU230544B1 (zh)
IL (2) IL155483A0 (zh)
MX (1) MXPA03004394A (zh)
PL (1) PL224371B1 (zh)
RU (1) RU2312858C2 (zh)
WO (2) WO2002042265A2 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
BR0309988A (pt) * 2002-05-17 2005-02-22 Leo Pharma As Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
CA2485351C (en) * 2002-05-17 2011-12-06 Leo Pharma A/S Cyanoguanidine prodrugs
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
CA2518916A1 (en) * 2003-04-03 2004-10-21 Joseph R. Garlich Pi-3 kinase inhibitor prodrugs
JP5189367B2 (ja) 2004-12-22 2013-04-24 レオ ファーマ アクティーゼルスカブ 新規シアノグアニジン化合物
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
EP2197443A4 (en) * 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHODS FOR INFLUENCING NAD + CONTENT USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE INHIBITOR
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
EP2342181A1 (en) 2008-08-29 2011-07-13 Topo Target A/S Novel urea and thiourea derivatives
AU2010210248B2 (en) 2009-02-06 2012-08-16 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof
JP2012533530A (ja) 2009-07-17 2012-12-27 トポターゲット・アクティーゼルスカブ ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
KR20140020823A (ko) 2010-09-03 2014-02-19 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 구아니딘 화합물 및 조성물
US9359376B2 (en) * 2011-04-08 2016-06-07 Sphaera Pharma Pte. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
CN106905297A (zh) * 2012-06-15 2017-06-30 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
BR112014032917A2 (pt) * 2012-06-27 2017-06-27 Alzheimers Inst Of America Inc compostos e usos terapêuticos dos mesmos
WO2014055938A1 (en) * 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
WO2018199174A1 (ja) * 2017-04-25 2018-11-01 生化学工業株式会社 第3級アミン化合物又はイミン化合物-ポリマーコンジュゲートとその製造方法
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11136295B2 (en) * 2018-10-29 2021-10-05 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000093A1 (en) * 1989-06-26 1991-01-10 The Research Foundation Of State University Of New York Bis-acyloxymethyl derivatives
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4080300A (en) 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds

Also Published As

Publication number Publication date
HU230544B1 (hu) 2016-11-28
WO2002042276A1 (en) 2002-05-30
EP2894149B1 (en) 2017-08-02
WO2002042265A3 (en) 2002-08-15
CN1589262A (zh) 2005-03-02
AU2002214947B2 (en) 2007-02-15
AU2002223511A1 (en) 2002-06-03
EP1339686B1 (en) 2015-09-16
ES2549260T3 (es) 2015-10-26
CA2426601C (en) 2015-01-13
KR20030051861A (ko) 2003-06-25
CZ305764B6 (cs) 2016-03-09
WO2002042265A2 (en) 2002-05-30
US20020165201A1 (en) 2002-11-07
JP2004520282A (ja) 2004-07-08
IL155483A0 (en) 2003-11-23
AU1494702A (en) 2002-06-03
RU2312858C2 (ru) 2007-12-20
KR100871577B1 (ko) 2008-12-02
CA2426601A1 (en) 2002-05-30
EP2894149A1 (en) 2015-07-15
MXPA03004394A (es) 2004-04-20
HUP0400564A3 (en) 2008-03-28
US6525077B2 (en) 2003-02-25
IL155483A (en) 2010-12-30
HK1073297A1 (en) 2005-09-30
PL362864A1 (en) 2004-11-02
BR0115514A (pt) 2003-12-30
PL224371B1 (pl) 2016-12-30
HUP0400564A2 (hu) 2004-06-28
CZ20031303A3 (en) 2004-04-14
JP4521157B2 (ja) 2010-08-11
ES2643083T3 (es) 2017-11-21
EP1339686A2 (en) 2003-09-03
CN100368401C (zh) 2008-02-13

Similar Documents

Publication Publication Date Title
HK1212678A1 (zh) 雙氰胺前體藥物
IL151073A0 (en) Antiviral prodrugs
GB0002847D0 (en) Ampligier arrangement
AU3391801A (en) Pyridinylimidazoles
DZ3293A1 (fr) Arylpyrazines substitues
AU6227101A (en) Substituted iminoazines
IL151010A0 (en) Linezolid-crystal form ii
AU6803901A (en) Bis-arylsulfones
PL358119A1 (en) Substituted phenyluracils
PL372761A1 (en) Cyanoguanidine prodrugs
AU5825501A (en) Substituted benzoylcyclohexenones
AU6619001A (en) Liquid-pourers
EP1343494A4 (en) PROMOTERS TETRAPARTATES
AU4686401A (en) Hypotensors
AU4831301A (en) Gm-negative ehv-mutants
AU2360402A (en) Substituted phenyluracils
GB0111284D0 (en) Grating
SI1261613T1 (en) Gastro-specific prodrugs
AU1852P (en) Tickit xTriticosecale
AU2117P (en) Gauka Gaura lindheimeri
AU1702P (en) Trailblazer Xanthostemon chrysanthus
GB0027368D0 (en) Order form
GB0015191D0 (en) Advance arrangement
GB0015193D0 (en) Advance arrangement
GB0130486D0 (en) Windbeater one

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211113